Navigation Links
Novel method to reveal drug targets
Date:2/22/2008

from these proteins simply because there was no efficient method to examine them. Effectively, a swathe of clinically important targets is invisible to research.

"AVEXIS now allows us to scale the hunt for biologically and clinically important protein-protein interactions," continues Dr Wright. "These interactions are like Velcro - each hook can bind only weakly, but together, they can have a very strong effect. We increased the strength by gathering the proteins together, as in a small scrap of Velcro."

The team identified previously undescribed interactions in a class of proteins called the immunoglobulin superfamily: this group of proteins shares properties that are important to allow cells to respond to their environment, talk to one another and stick together. Using human proteins and zebrafish as a model, the Sanger Institute researchers looked at interactions between 110 proteins in this superfamily - a total of more than 6000 experiments.

They found 17 interactions that met stringent standards of reliability, several of which would last for less than 0.1 seconds in cells. For each, they looked to see where the proteins were located in zebrafish embryos. They found, broadly, two categories; those in which both protein partners are present in the same tissue (and likely to be involved in cell adhesion) and those in which they are present in adjoining tissues (and therefore likely to be involved in communication between tissues). Half of the proteins interact with more than one other protein, forming interaction networks.

The results provide the first network of low-affinity interactions between proteins on the cell surface and the first set of extensive data in the zebrafish, a leading organism for following visually the effects of gene disruption.

"AVEXIS is not restricted to only one specific organism and could be used in many contexts," explains Dr Wright. "We found in the zebrafish novel interactions for well-s
'/>"/>

Contact: Don Powell
don@sanger.ac.uk
44-012-234-96928
Wellcome Trust Sanger Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NJ (PRWEB) August 01, 2014 ... web portal that aims to empower patients and ... in their health care by providing easy, secure ... Portal gives patients instant, web-based access to their ... and radiology results, medications, allergies, demographic information, visit ...
(Date:8/1/2014)... procedures have grown in popularity as more and more ... toxin generally known as BOTOX use ... have emerged to perform procedures utilizing this and other ... from the Division of Plastic Surgery Presbyterian Hospital in ... University in New York have assessed the capability of ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 St. Christopher's ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , St. Christopher's Hospital ... services for children from birth through 21 years of ... several of the hospital's specialties, including autism and childhood ...
(Date:8/1/2014)... Narconon Arrowhead recently celebrated the occasion ... drug rehab center located in the small town of ... is the flagship drug rehab center in the Narconon ... for services there. Now, with such a long track ... as well as client reviews showing the effectiveness of ...
(Date:8/1/2014)... TX (PRWEB) August 01, 2014 Delta ... the Year for its outstanding commitment to St. Jude ... the hospital since 1999 and pledging to raise another ... combat childhood cancer and other deadly diseases. , ... any single partner in St. Jude history. Specifically, it ...
Breaking Medicine News(10 mins):Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3
... that vitamin C was vital for good health and could ... ,Dr Margret Vissers, from Otago University's Free Radical Research ... vitamin C was a vital part of healthy living and ... had a cold. ,"I've found that vitamin C ...
... nerve cells in the brain and lead to depression, according to ... and Science in North Chicago. ,The team led by Daniel ... rats for 20 minutes. The older rats quickly cornered, pinned down ... ,The younger rats became fearful and acted depressed in the ...
... below seven is fast depleting, which has sent the Ministry of ... Company CSL had stopped the production of the Tet-tox vaccine in ... is just enough to last till the end of this month. ... drugs will have to be used by those who are in ...
... New research suggests that a child’s race may ... tobacco toxins associated with environmental tobacco smoke (ETS). ... asthma, who are exposed to ETS, have significantly ... counterparts. ,“African American children suffer from ...
... question of bloodshot eyes anymore. After sleepless nights, a person’s ... has been found//. ,Sleep deprivation lowers metabolic ... colleagues at Walter Reed Army Institute of Research, report in ... group of volunteers to two sleepless nights, they found that ...
... Patients can start using their mobile phones when the ban ... in the hospitals because it was believed// that its electromagnetic ... per the directive issued from the Department of Health, cell ... equipments. ,This announcement has brought in cheer ...
Cached Medicine News:Health News:Vitamin C Could Help in Curbing Cancer 2Health News:Race Affects Tobacco Absorption in Children 2
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant,s subsidiaries, Valeant Pharmaceuticals North America LLC ... signed an agreement to acquire the assets of ...  Valeant will pay Janssen $345 million for the ...
... Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that ... the following letter to shareholders. (Photo: ... Last December, I authored a shareholder letter which ... need for innovative new therapeutic strategies to evolve as ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 2Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 3Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: